Edison Pharmaceuticals Lands $20,000,000 Series F Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=934d32f0-a7a9-4c0f-a989-7ab81500d47e&Preview=1 -
Date
11/27/2012 -
Company Name
Edison Pharmaceuticals -
Mailing Address
350 N. Bernardo Ave. Mountain View, CA 94043 -
Company Description
Edison’s business is the development of drugs to treat diseases that impair energy metabolism. Energy impairment diseases can be classified on the basis of whether they are inherited or acquired, and furthermore on the location of the defect. Edison is initially focusing on inherited diseases of the mitochondria- nature’s biological energy substation. -
Website
http://www.edisonpharma.com -
Transaction Type
Venture Equity -
Transaction Amount
$20,000,000 -
Transaction Round
Series F -
Proceeds Purposes
Proceeds will be used to advance the clinical development of EPI-743. The company has recently announced the initiation of phase 2B clinical trials in the United States in two orphan mitochondrial diseases, Leigh syndrome and Friedreich’s ataxia. Additional clinical development initiatives are underway and will be announced in Q1 2013. -
M&A Terms
-
Venture Investor
Mitsui & Co. -
Venture Investor
Undisclosed
